STOCK TITAN

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Kodiak Sciences (Nasdaq: KOD) reported its Q1 2024 financial results and business highlights. The company is advancing its clinical programs for tarcocimab, KSI-501, and KSI-101. Key developments include the initiation of the GLOW2 Phase 3 study for diabetic retinopathy and plans to start the DAYBREAK Phase 3 study for wet AMD. Kodiak also highlighted progress in its duet and triplet platforms at the ARVO 2024 Annual Meeting. Financially, Kodiak ended the quarter with $245.9 million in cash. The net loss decreased to $43.0 million, or $0.82 per share, compared to $70.8 million the previous year. R&D expenses dropped to $29.9 million from $56.5 million, while G&A expenses also decreased slightly to $16.1 million.

Positive
  • Kodiak's cash position is strong at $245.9 million, supporting operations into 2026.
  • Net loss decreased significantly to $43.0 million from $70.8 million in the previous year.
  • R&D expenses reduced to $29.9 million from $56.5 million.
  • Initiation of GLOW2 Phase 3 study for diabetic retinopathy.
  • Planned start of DAYBREAK Phase 3 study for wet AMD.
  • Progress in duet and triplet platforms presented at ARVO 2024 Annual Meeting.
  • Successful manufacturing of KSI-501 and KSI-101 clinical materials.
Negative
  • Net loss remains at $43.0 million, indicating ongoing financial losses.
  • R&D expenses, although reduced, still significant at $29.9 million.
  • G&A expenses at $16.1 million, reflecting high operational costs.
  • The requirement for two pivotal clinical studies for KSI-101 may delay market entry.

Kodiak Sciences reported a net loss of $43.0 million for Q1 2024, an improvement from the $70.8 million net loss in Q1 2023. This reduction is partly due to a significant decrease in R&D expenses, which fell from $56.5 million to $29.9 million. This drop was primarily driven by reduced clinical activities for tarcocimab and forfeiture-related stock-based compensation expenses.

The company maintains a strong cash position with $245.9 million in cash and equivalents, projected to sustain operations through 2026. This is a stabilizing factor for investors, indicating that Kodiak has the necessary funds to continue its research and development without immediate financing needs.

While the reduction in R&D expenses may initially seem positive, it's essential to consider whether these cuts could impact future product development timelines. Long-term investors should weigh the balance between current cash management and the potential delays in bringing new treatments to market.

Rating: 1

Kodiak's ongoing clinical trials, particularly the GLOW2 and DAYBREAK studies and the upcoming APEX study for KSI-101, are critical developments. The introduction of tarcocimab and KSI-501 in Phase 3 studies, targeting conditions like diabetic retinopathy and wet AMD, showcases potential advancements in ophthalmology treatments. The DAYBREAK study's non-inferiority design against aflibercept is particularly notable, as it may position Kodiak's therapies competitively in the market.

The unique approach of the duet and triplet platforms, which allows for targeted, multi-specific modulation of biological pathways, could potentially revolutionize treatments for ophthalmic and systemic diseases. This innovation could offer targeted treatments with fewer side effects, a significant advantage over existing therapies.

However, with new Phase 1b and pivotal study initiations, there's inherent risk and uncertainty. Investors should be aware that while the scientific developments are promising, the outcomes of these studies are vital to the long-term success of Kodiak's portfolio.

Rating: 1

The market potential for Kodiak’s products is expansive, particularly in the ophthalmology sector. The company’s strategic focus on developing treatments for conditions like diabetic retinopathy and macular edema positions it well within a rapidly growing market. However, it's important to note that the sector is highly competitive, with established players like Regeneron and Novartis providing significant competition.

The advancements in proprietary platforms like duet and triplet, which allow for modular, multi-specific drug designs, present a unique selling proposition. These platforms could enable Kodiak to deliver innovative treatments that may garner substantial market interest if proven effective in clinical trials.

From a commercial standpoint, the company’s progress in manufacturing readiness, particularly the release of tarcocimab and KSI-501 drug products for Phase 3 studies, is reassuring. This indicates preparedness for potential market entry, pending successful trial outcomes and regulatory approvals.

Investors should pay close attention to upcoming clinical milestones and FDA feedback, as these will be pivotal in assessing the potential market impact of Kodiak’s pipeline.

Rating: 1

PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.

"We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We are enrolling well in GLOW2 and remain on track to activate mid-year our next Phase 3 study DAYBREAK in wet AMD which is designed to investigate the efficacy, durability and safety of tarcocimab and KSI-501 in parallel against aflibercept. We also expect to initiate Phase 1b enrollment in June for the APEX study of KSI-101, our anti-IL-6, VEGF-trap bispecific protein, in patients with macular edema associated with inflammation."

"We were pleased to share the advancement on our growing repertoire of novel small molecules and biologics for the duet and triplet platforms at the ARVO 2024 Annual Meeting recently. The duets and triplets are designed as a modular platform that embeds diverse active pharmaceutical ingredients ("API") including small molecules, proteins, peptides, macrocycles, and oligonucleotides in the biopolymer backbone to enable high drug antibody ratio ("DAR") medicines with targeted, multi-specific, tailored modulation of biological pathways for ophthalmic and systemic diseases."

"We look forward to sharing ongoing progress of our late- and early-phase retina pipeline programs later this year, as we refine our planning and continue to accelerate our execution," concluded Dr. Perlroth.

Recent Business Highlights

  • Recent scientific presentations: We presented a breadth of data on our early- and late-phase retina pipeline at the Association for Research in Vision and Ophthalmology ("ARVO") 2024 Annual Meeting. Our presentations included clinical and non-clinical data on our ABC Platform investigational medicines tarcocimab and KSI-501, and we highlighted progress on our duet and triplet platform including discovery and characterization of novel small molecules and biologics.

  • Tarcocimab pivotal program: We announced in the first quarter of 2024 that we intend to conduct two additional Phase 3 clinical studies with tarcocimab. The GLOW2 Phase 3 study in diabetic retinopathy ("DR") has a similar design to the successful GLOW1 Phase 3 study with the benefit of an additional, third monthly loading dose (weeks 0, 4, and 8). We recently announced that the first patients were treated in the GLOW2 study and that our goal is to complete enrollment before the end of this year.

    We also announced our intention to study tarcocimab as a second investigational arm in the KSI-501 Phase 3 DAYBREAK study to evaluate its durability, strengthen its competitive position in wet AMD and bolster its ex-US regulatory dossier. We are operationalizing towards DAYBREAK study activation in mid-2024.

    Both GLOW2 and DAYBREAK will be run using our go-to-market formulation of tarcocimab, which we believe improves the manufacturability in a prefilled syringe and may also enhance the utility of the product.
  • Tarcocimab commercial scale manufacturing: We released tarcocimab drug product based on the go-to-market formulation in March 2024, which is ready for use in the GLOW2 and DAYBREAK Phase 3 studies.

  • KSI-501 clinical program: In the first quarter of 2024 we shared the Phase 1 study results of KSI-501 in patients with diabetic macular edema ("DME") at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting. The Phase 1 study demonstrated that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained visual acuity gains and fluid reduction in patients.

    We also announced our intention of advancing KSI-501 into the Phase 3 DAYBREAK study to evaluate its efficacy, durability, and safety in wet AMD. The DAYBREAK study is intended to be a non-inferiority study evaluating KSI-501 dosed every 4 to 24 weeks, compared to aflibercept. The study will use an enhanced formulation of KSI-501 informed from tarcocimab commercial manufacturing scale-up. We are on track for study activation in mid-2024.

  • KSI-101 clinical program: KSI-101 is a novel, potent and high-strength bispecific protein targeting IL-6 and VEGF. In the first quarter of 2024 we announced our intention to develop KSI-101 for patients who have retinal fluid and inflammation. With KSI-101, we are seeking to develop an intravitreal biologic therapy whose commercial opportunity sits outside of today's anti-VEGF retina market. We have recently obtained supportive FDA feedback on the pivotal study program for KSI-101. Two pivotal clinical studies will be required, both with 16-week primary endpoints. We are on track to initiate enrollment for a dose-finding Phase 1b APEX study in June 2024 to evaluate the safety and tolerability and to identify two dose levels to progress into dual Phase 2b/3 studies (PEAK and PINNACLE) which we hope to initiate later in 2024.

  • KSI-501 and KSI-101 manufacturing: We have been progressing the manufacturing of KSI-501 and KSI-101 in preparation for their anticipated clinical studies. Clinical material for both KSI-501 (50 mg/mL strength in our enhanced formulation) and KSI-101 (100 mg/mL strength) have been successfully manufactured and released.

First Quarter 2024 Financial Results

Cash Position

Kodiak ended the first quarter of 2024 with $245.9 million of cash and cash equivalents. We believe that our current cash will support our current and planned operations into 2026.

Net Loss

The net loss for the first quarter of 2024 was $43.0 million, or $0.82 per share on both a basic and diluted basis, as compared to a net loss of $70.8 million, or $1.35 per share on both a basic and diluted basis, for the first quarter of 2023. The net loss for the quarter ended March 31, 2024 included non-cash stock-based compensation of $18.4 million, as compared to $26.0 million for the quarter ended March 31, 2023.

R&D Expenses

Research and development (R&D) expenses were $29.9 million for the first quarter of 2024, as compared to $56.5 million for the first quarter of 2023. The R&D expenses for the first quarter of 2024 included non-cash stock-based compensation of $8.7 million, as compared to $14.7 million for the first quarter of 2023. The decrease in R&D expenses for the first quarter of 2024, as compared to the same period in 2023, was primarily driven by reduced clinical activities for tarcocimab, as well as forfeitures related to stock-based compensation expense.

G&A Expenses

General and administrative (G&A) expenses were $16.1 million for the first quarter of 2024, as compared to $18.1 million for the first quarter of 2023. The G&A expenses for the first quarter of 2024 included non-cash stock-based compensation of $9.7 million, as compared to $11.3 million for the first quarter of 2023.

About tarcocimab tedromer (tarcocimab, KSI-301)

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate ("ABC") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's immediate objective with tarcocimab is to finish the clinical development program to enable marketing authorization application for the retinal vascular diseases of diabetic retinopathy, retinal vein occlusion and wet AMD. We believe tarcocimab can fill an important unmet need in the marketplace for a medicine that can be administered to treatment naïve and/or treatment experienced patients on a monthly through every 6-month interval, and with the majority of patients able to do well on every 6-month dosing.

To date, tarcocimab has completed three successful Phase 3 pivotal clinical studies: the Phase 3 GLOW1 study in diabetic retinopathy ("DR"), the Phase 3 BEACON study in retinal vein occlusion ("RVO") and the Phase 3 DAYLIGHT study in wet AMD. In the GLOW1 study, 100% of tarcocimab treated patients were extended to 6-month dosing. In the BEACON study, in the first 6 months tarcocimab-treated patients were dosed on an every 8-week interval (as opposed to an every 4-week interval for aflibercept) and in the second 6-months nearly half of patients did not require treatment at all, and with both groups achieving overlapping vision outcomes at one year.

Kodiak is initiating two additional BLA-facing Phase 3 studies: the GLOW2 study in diabetic retinopathy, and the DAYBREAK study in wet AMD. The GLOW2 study has a similar design as GLOW1 with the benefit of an additional, third monthly loading dose (weeks 0, 4 and 8) to explore even further benefits with tarcocimab in diabetic retinopathy patients. The DAYBREAK study will include investigational arms for tarcocimab and KSI-501, Kodiak's bispecific conjugate, to evaluate their efficacy, safety and durability versus aflibercept. DAYBREAK is designed to strengthen the competitive position of tarcocimab in wet AMD and bolster the ex-US regulatory dossier for the program. Both GLOW2 and DAYBREAK will use a go-to-market formulation of tarcocimab which we believe improves the manufacturability in a prefilled syringe and may also enhance the utility of the product. GLOW2 is actively enrolling patients, and we are operationalizing towards DAYBREAK study activation in mid-2024. 

About KSI-501

KSI-501 is an anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting multiple disease biologies. A completed Phase 1 multiple ascending dose study demonstrated that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained improvement in visual acuity and fluid reduction in patients with diabetic macular edema. 

Kodiak intends to advance KSI-501 into a Phase 3 study DAYBREAK in 2024 to evaluate its efficacy, durability, and safety in wet AMD. The DAYBREAK study is intended to be a non-inferiority study evaluating KSI-501 dosed every 4 to 24 weeks, compared to aflibercept dosed per label. The DAYBREAK study will use an enhanced formulation of KSI-501 educated from tarcocimab's commercial manufacturing scale-up. We are operationalizing towards DAYBREAK study activation in mid-2024.

About KSI-101

KSI-101 is the unconjugated protein portion of KSI-501 and is a novel, potent and high strength bispecific protein targeting IL-6 and VEGF. We intend to develop KSI-101 for patients who have retinal fluid and inflammation. Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that retinal inflammatory conditions represent a new market segment separate from the established anti-VEGF market. KSI-101 is a clinical prospect with opportunities and risks uncoupled from the ABC Platform, and as such is an important part of our late-phase portfolio. We intend to initiate a dose-finding Phase 1b study APEX in the second quarter of 2024 to evaluate its safety and tolerability and to identify two dose levels to progress into dual Phase 2b/3 studies PEAK and PINNACLE, both with a 16-week primary endpoint, later in 2024.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies.

Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases including diabetic retinopathy, the leading cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world.

KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting multiple disease biologies for differentiated efficacy. Phase 1b data for KSI-501 was presented in February 2024, and the Phase 3 DAYBREAK study of KSI-501 in wet AMD is scheduled to be actively screening patients in mid-2024.

Additionally, Kodiak is developing a third product candidate, KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the unconjugated protein portion of KSI-501. Kodiak intends to develop KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina.

Kodiak has expanded its early research pipeline of duet and triplet inhibitors that embed small molecules and other active pharmaceutical ingredients ("API") in the biopolymer backbone to enable targeted, high drug-antibody ratio ("DAR") medicines. The diverse API's are designed to be released over time to achieve targeted, multi-specific and tailored modulation of targeted biological pathways. The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial ophthalmic and systemic diseases.

For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the potential benefits of KSI-501, including that it may represent a new category of retinal medicines with greater therapeutic efficacy than existing therapies; the prospects of the candidates in our pipeline, including tarcocimab, KSI-501, and KSI-101; our ability to apply our clinical experience with tarcocimab to allow us to design and run an additional pivotal study, and the potential success of such study; the timing of activation and completion of our planned and ongoing studies, and our guidance on our cash runway. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "could," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. The risks and uncertainties include, but are not limited to: the risk that cessation or delay of any of the on-going clinical studies and our development of tarcocimab or KSI-501 may occur; the risk that the BEACON and/or GLOW1 and/or GLOW2 and/or DAYLIGHT results may not provide the evidence, insights, or benefits as anticipated; the risk that safety, efficacy, and durability data observed in our product candidates in current or prior studies may not continue or persist; the risk that the results of the tarcocimab Phase 3 studies may not be sufficient to support a single Biologics License Application (BLA) submission for wet AMD, RVO and NPDR; the risk that a BLA may not be accepted by, or receive approval from, the FDA or foreign regulatory agencies when expected, or at all; future potential regulatory milestones of tarcocimab or KSI-501 or KSI-101, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the risk that a new formulation of tarcocimab, KSI-501 or other ABC Platform derived molecules may not provide the benefits expected; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; the risk that KSI-501 may not inhibit VEGF and IL-6 or have an impact on the treatment of patients as expected; any one or more of our product candidates may not be successfully developed, approved or commercialized; our manufacturing facilities may not operate as expected; adverse conditions in the general domestic and global economic markets, which may significantly impact our business and operations, including our clinical trial sites, as well as the business or operations of our manufacturers, contract research organizations or other third parties with whom we conduct business; as well as the other risks Identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™, and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

 

Kodiak Sciences Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(Unaudited)






Three Months Ended
March 31,




2024



2023


Operating expenses







Research and development


$

29,931



$

56,520


General and administrative



16,124




18,095


Total operating expenses



46,055




74,615


Loss from operations



(46,055)




(74,615)


Interest income



3,353




3,617


Interest expense






(4)


Other income (expense), net



(337)




222


Net loss


$

(43,039)



$

(70,780)


Net loss per common share, basic and diluted


$

(0.82)



$

(1.35)


Weighted-average shares of common stock
     outstanding used in computing net loss per
     common share, basic and diluted



52,510,460




52,337,603


 

Kodiak Sciences Inc.

Condensed Consolidated Balance Sheet Data

(in thousands)

(Unaudited)






March 31,
2024



December 31,
2023


Cash and cash equivalents


$

245,919



$

285,507


Working capital


$

226,657



$

247,580


Total assets


$

434,759



$

479,372


Accumulated deficit


$

(1,195,570)



$

(1,152,531)


Total stockholders' equity


$

241,189



$

265,781


 

 

Cision View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-announces-recent-business-highlights-and-first-quarter-2024-financial-results-302146792.html

SOURCE Kodiak Sciences Inc.

FAQ

What are Kodiak Sciences' recent business highlights?

Kodiak Sciences reported advancements in its clinical programs for tarcocimab, KSI-501, and KSI-101, including the initiation of the GLOW2 Phase 3 study and plans for the DAYBREAK Phase 3 study.

What were Kodiak Sciences' financial results for Q1 2024?

Kodiak Sciences reported a net loss of $43.0 million, or $0.82 per share, for Q1 2024. The company ended the quarter with $245.9 million in cash.

What progress has Kodiak Sciences made in its clinical programs?

Kodiak Sciences has initiated the GLOW2 Phase 3 study for diabetic retinopathy and plans to start the DAYBREAK Phase 3 study for wet AMD. They also highlighted progress in their duet and triplet platforms.

What is the cash position of Kodiak Sciences as of Q1 2024?

Kodiak Sciences ended Q1 2024 with $245.9 million in cash and cash equivalents.

How did Kodiak Sciences' R&D expenses change in Q1 2024?

R&D expenses decreased to $29.9 million in Q1 2024 from $56.5 million in the same period last year.

What upcoming studies are planned for Kodiak Sciences' clinical programs?

Kodiak Sciences plans to start the DAYBREAK Phase 3 study for wet AMD and initiate Phase 1b enrollment for the APEX study of KSI-101 in June 2024.

What challenges does Kodiak Sciences face with its KSI-101 program?

Kodiak Sciences needs to conduct two pivotal clinical studies for KSI-101, which may delay its market entry.

Kodiak Sciences Inc

NASDAQ:KOD

KOD Rankings

KOD Latest News

KOD Stock Data

137.85M
52.62M
5.66%
76.95%
3.54%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PALO ALTO